<DOC>
	<DOCNO>NCT01099085</DOCNO>
	<brief_summary>Based antitumor activity statin , design phase III study capecitabine/CDDP chemotherapy plus low-dose simvastatin equivalent cardiovascular dose advance gastric cancer patient .</brief_summary>
	<brief_title>Trial XP ( Capecitabine/CDDP ) Simvastatin Advanced Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1. histologically cytologically confirm diagnosis gastric adenocarcinoma gastroesophageal junction adenoca ( i.e . adenocarcinoma &gt; 50 % extension stomach ) 2. patient must present stage IV disease amenable surgery , radiation combine modality therapy curative intent . Patients previously undergo local treatment ( surgery and/or radiation ) must subsequently progress recur 3. measurable evaluable disease accord RECIST 4. age , 18 year old 5 . ECOG performance status 0 2 6. adequate organ function define follow criterion absolute neutrophil count ( ANC ) ≥ 1,500/ul platelet ≥ 100,000/ul AST/ALT ≤ 2.5 x ULN , ≤ 5.0 x ULN liver involvement Total serum bilirubin ≤ 3.0 mg/dL 7. sign write informed consent 1. severe comorbid illness and/or active infection 2. pregnant lactate woman 3. active CNS metastasis controllable radiotherapy corticosteroid 4. active uncontrollable bleed gastrointestinal tract 5. known history hypersensitivity study drug 6. patient already statin treatment hyperlipidemia control ( ≥ 1 year interval last statin dose , patient eligible study entry )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastric cancer , unresectable/metastatic</keyword>
</DOC>